nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—peripheral nervous system neoplasm	0.44	1	CbGaD
Carfilzomib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0418	0.239	CbGbCtD
Carfilzomib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0418	0.239	CbGbCtD
Carfilzomib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.029	0.166	CbGbCtD
Carfilzomib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0178	0.102	CbGbCtD
Carfilzomib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0166	0.0953	CbGbCtD
Carfilzomib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0164	0.0937	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0112	0.0639	CbGbCtD
Carfilzomib—Pentagastrin—BCHE—peripheral nervous system neoplasm	0.00419	0.696	CrCbGaD
Carfilzomib—PSMB10—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00279	0.474	CbGdCrCtD
Carfilzomib—PSMB8—trigeminal ganglion—peripheral nervous system neoplasm	0.00218	0.117	CbGeAlD
Carfilzomib—PSMB8—parotid gland—peripheral nervous system neoplasm	0.00206	0.111	CbGeAlD
Carfilzomib—PSMB5—trigeminal ganglion—peripheral nervous system neoplasm	0.00193	0.104	CbGeAlD
Carfilzomib—PSMB5—parotid gland—peripheral nervous system neoplasm	0.00182	0.0978	CbGeAlD
Carfilzomib—PSMB1—trigeminal ganglion—peripheral nervous system neoplasm	0.00168	0.0906	CbGeAlD
Carfilzomib—PSMB2—trigeminal ganglion—peripheral nervous system neoplasm	0.00164	0.0884	CbGeAlD
Carfilzomib—PSMB1—parotid gland—peripheral nervous system neoplasm	0.00159	0.0855	CbGeAlD
Carfilzomib—PSMB2—parotid gland—peripheral nervous system neoplasm	0.00155	0.0834	CbGeAlD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.00155	0.263	CbGdCrCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00155	0.263	CbGdCrCtD
Carfilzomib—PSMB10—cerebellum—peripheral nervous system neoplasm	0.00148	0.0795	CbGeAlD
Carfilzomib—Lopinavir—ABCB1—peripheral nervous system neoplasm	0.000994	0.165	CrCbGaD
Carfilzomib—PSMB5—cerebellum—peripheral nervous system neoplasm	0.000841	0.0452	CbGeAlD
Carfilzomib—Ritonavir—ABCB1—peripheral nervous system neoplasm	0.000836	0.139	CrCbGaD
Carfilzomib—PSMB1—cerebellum—peripheral nervous system neoplasm	0.000735	0.0395	CbGeAlD
Carfilzomib—PSMB2—cerebellum—peripheral nervous system neoplasm	0.000717	0.0386	CbGeAlD
Carfilzomib—Thrombocytopenia—Topotecan—peripheral nervous system neoplasm	0.000458	0.00213	CcSEcCtD
Carfilzomib—Infection—Melphalan—peripheral nervous system neoplasm	0.000455	0.00212	CcSEcCtD
Carfilzomib—Thrombocytopenia—Tretinoin—peripheral nervous system neoplasm	0.000454	0.00212	CcSEcCtD
Carfilzomib—Thrombocytopenia—Isotretinoin—peripheral nervous system neoplasm	0.000454	0.00212	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—peripheral nervous system neoplasm	0.000451	0.0021	CcSEcCtD
Carfilzomib—Thrombocytopenia—Melphalan—peripheral nervous system neoplasm	0.000448	0.00209	CcSEcCtD
Carfilzomib—Anorexia—Topotecan—peripheral nervous system neoplasm	0.000446	0.00208	CcSEcCtD
Carfilzomib—Chills—Alitretinoin—peripheral nervous system neoplasm	0.000444	0.00207	CcSEcCtD
Carfilzomib—Cardiac disorder—Vincristine—peripheral nervous system neoplasm	0.000442	0.00206	CcSEcCtD
Carfilzomib—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.000442	0.00206	CcSEcCtD
Carfilzomib—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.000442	0.00206	CcSEcCtD
Carfilzomib—Anorexia—Melphalan—peripheral nervous system neoplasm	0.000436	0.00203	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—peripheral nervous system neoplasm	0.000433	0.00202	CcSEcCtD
Carfilzomib—Anaemia—Dactinomycin—peripheral nervous system neoplasm	0.000429	0.002	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.000426	0.00199	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—peripheral nervous system neoplasm	0.000424	0.00198	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—peripheral nervous system neoplasm	0.000423	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.000422	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000422	0.00197	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—peripheral nervous system neoplasm	0.000422	0.00197	CcSEcCtD
Carfilzomib—Insomnia—Isotretinoin—peripheral nervous system neoplasm	0.000419	0.00195	CcSEcCtD
Carfilzomib—Insomnia—Tretinoin—peripheral nervous system neoplasm	0.000419	0.00195	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.000417	0.00194	CcSEcCtD
Carfilzomib—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.000417	0.00194	CcSEcCtD
Carfilzomib—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.000416	0.00194	CcSEcCtD
Carfilzomib—Leukopenia—Dactinomycin—peripheral nervous system neoplasm	0.000416	0.00194	CcSEcCtD
Carfilzomib—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.000413	0.00193	CcSEcCtD
Carfilzomib—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.000413	0.00193	CcSEcCtD
Carfilzomib—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.000408	0.0019	CcSEcCtD
Carfilzomib—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.000406	0.00189	CcSEcCtD
Carfilzomib—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.000403	0.00188	CcSEcCtD
Carfilzomib—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.000403	0.00188	CcSEcCtD
Carfilzomib—Fatigue—Topotecan—peripheral nervous system neoplasm	0.000403	0.00188	CcSEcCtD
Carfilzomib—Back pain—Vincristine—peripheral nervous system neoplasm	0.000401	0.00187	CcSEcCtD
Carfilzomib—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.0004	0.00186	CcSEcCtD
Carfilzomib—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.0004	0.00186	CcSEcCtD
Carfilzomib—Pain—Topotecan—peripheral nervous system neoplasm	0.0004	0.00186	CcSEcCtD
Carfilzomib—Constipation—Topotecan—peripheral nervous system neoplasm	0.0004	0.00186	CcSEcCtD
Carfilzomib—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.000398	0.00186	CcSEcCtD
Carfilzomib—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.000398	0.00185	CcSEcCtD
Carfilzomib—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000396	0.00185	CcSEcCtD
Carfilzomib—Pain—Tretinoin—peripheral nervous system neoplasm	0.000396	0.00185	CcSEcCtD
Carfilzomib—Pain—Isotretinoin—peripheral nervous system neoplasm	0.000396	0.00185	CcSEcCtD
Carfilzomib—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000396	0.00185	CcSEcCtD
Carfilzomib—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000395	0.00184	CcSEcCtD
Carfilzomib—Pain—Melphalan—peripheral nervous system neoplasm	0.000391	0.00182	CcSEcCtD
Carfilzomib—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000391	0.00182	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—peripheral nervous system neoplasm	0.000384	0.00179	CcSEcCtD
Carfilzomib—Anaemia—Vincristine—peripheral nervous system neoplasm	0.000383	0.00179	CcSEcCtD
Carfilzomib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000377	0.00176	CcSEcCtD
Carfilzomib—Cough—Alitretinoin—peripheral nervous system neoplasm	0.000376	0.00175	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—peripheral nervous system neoplasm	0.000374	0.00174	CcSEcCtD
Carfilzomib—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000372	0.00173	CcSEcCtD
Carfilzomib—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.000371	0.00173	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000371	0.00173	CcSEcCtD
Carfilzomib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000369	0.00172	CcSEcCtD
Carfilzomib—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000367	0.00171	CcSEcCtD
Carfilzomib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000367	0.00171	CcSEcCtD
Carfilzomib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000367	0.00171	CcSEcCtD
Carfilzomib—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000361	0.00168	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000358	0.00167	CcSEcCtD
Carfilzomib—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000358	0.00167	CcSEcCtD
Carfilzomib—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.000353	0.00164	CcSEcCtD
Carfilzomib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000349	0.00163	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—peripheral nervous system neoplasm	0.000348	0.00162	CcSEcCtD
Carfilzomib—Chills—Etoposide—peripheral nervous system neoplasm	0.000346	0.00161	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.00161	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000345	0.00161	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.000345	0.00161	CcSEcCtD
Carfilzomib—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000344	0.0016	CcSEcCtD
Carfilzomib—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000339	0.00158	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—peripheral nervous system neoplasm	0.000339	0.00158	CcSEcCtD
Carfilzomib—Infection—Vincristine—peripheral nervous system neoplasm	0.000336	0.00157	CcSEcCtD
Carfilzomib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000335	0.00156	CcSEcCtD
Carfilzomib—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000335	0.00156	CcSEcCtD
Carfilzomib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000333	0.00155	CcSEcCtD
Carfilzomib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000333	0.00155	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000332	0.00155	CcSEcCtD
Carfilzomib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000329	0.00154	CcSEcCtD
Carfilzomib—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.000328	0.00153	CcSEcCtD
Carfilzomib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000328	0.00153	CcSEcCtD
Carfilzomib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000327	0.00152	CcSEcCtD
Carfilzomib—Back pain—Etoposide—peripheral nervous system neoplasm	0.000325	0.00152	CcSEcCtD
Carfilzomib—Pain—Dactinomycin—peripheral nervous system neoplasm	0.000324	0.00151	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.000323	0.00151	CcSEcCtD
Carfilzomib—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000323	0.0015	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	0.000322	0.0015	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00032	0.00149	CcSEcCtD
Carfilzomib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00032	0.00149	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.00149	CcSEcCtD
Carfilzomib—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000318	0.00148	CcSEcCtD
Carfilzomib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000317	0.00148	CcSEcCtD
Carfilzomib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000317	0.00148	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.000314	0.00146	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—peripheral nervous system neoplasm	0.000314	0.00146	CcSEcCtD
Carfilzomib—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000313	0.00146	CcSEcCtD
Carfilzomib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000313	0.00146	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000313	0.00146	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000311	0.00145	CcSEcCtD
Carfilzomib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000309	0.00144	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000308	0.00144	CcSEcCtD
Carfilzomib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000307	0.00143	CcSEcCtD
Carfilzomib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000307	0.00143	CcSEcCtD
Carfilzomib—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000306	0.00143	CcSEcCtD
Carfilzomib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000305	0.00142	CcSEcCtD
Carfilzomib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000303	0.00141	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000301	0.0014	CcSEcCtD
Carfilzomib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.0003	0.0014	CcSEcCtD
Carfilzomib—Pain—Alitretinoin—peripheral nervous system neoplasm	0.0003	0.0014	CcSEcCtD
Carfilzomib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.0003	0.0014	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000297	0.00139	CcSEcCtD
Carfilzomib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000297	0.00139	CcSEcCtD
Carfilzomib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000297	0.00139	CcSEcCtD
Carfilzomib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000295	0.00137	CcSEcCtD
Carfilzomib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000295	0.00137	CcSEcCtD
Carfilzomib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000294	0.00137	CcSEcCtD
Carfilzomib—Cough—Etoposide—peripheral nervous system neoplasm	0.000293	0.00137	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000293	0.00137	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000293	0.00137	CcSEcCtD
Carfilzomib—Headache—Topotecan—peripheral nervous system neoplasm	0.000293	0.00136	CcSEcCtD
Carfilzomib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000292	0.00136	CcSEcCtD
Carfilzomib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000291	0.00136	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.00135	CcSEcCtD
Carfilzomib—Headache—Tretinoin—peripheral nervous system neoplasm	0.00029	0.00135	CcSEcCtD
Carfilzomib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00029	0.00135	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00029	0.00135	CcSEcCtD
Carfilzomib—Pain—Vincristine—peripheral nervous system neoplasm	0.00029	0.00135	CcSEcCtD
Carfilzomib—Constipation—Vincristine—peripheral nervous system neoplasm	0.00029	0.00135	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.00135	CcSEcCtD
Carfilzomib—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000285	0.00133	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.000285	0.00133	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000282	0.00131	CcSEcCtD
Carfilzomib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000278	0.00129	CcSEcCtD
Carfilzomib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000278	0.00129	CcSEcCtD
Carfilzomib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000275	0.00128	CcSEcCtD
Carfilzomib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000275	0.00128	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.00128	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000273	0.00127	CcSEcCtD
Carfilzomib—Infection—Etoposide—peripheral nervous system neoplasm	0.000272	0.00127	CcSEcCtD
Carfilzomib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000272	0.00127	CcSEcCtD
Carfilzomib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000272	0.00127	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.00126	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000269	0.00125	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000268	0.00125	CcSEcCtD
Carfilzomib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000267	0.00124	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.00123	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000261	0.00122	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.00122	CcSEcCtD
Carfilzomib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.00026	0.00121	CcSEcCtD
Carfilzomib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000259	0.00121	CcSEcCtD
Carfilzomib—Pain—Cisplatin—peripheral nervous system neoplasm	0.000256	0.00119	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000253	0.00118	CcSEcCtD
Carfilzomib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000252	0.00118	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000251	0.00117	CcSEcCtD
Carfilzomib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000251	0.0135	CbGeAlD
Carfilzomib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000245	0.00114	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000244	0.00114	CcSEcCtD
Carfilzomib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000243	0.00113	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000242	0.00113	CcSEcCtD
Carfilzomib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000241	0.00112	CcSEcCtD
Carfilzomib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00024	0.00112	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000238	0.00111	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000237	0.0011	CcSEcCtD
Carfilzomib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000237	0.0011	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000236	0.0011	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000236	0.0011	CcSEcCtD
Carfilzomib—Pain—Etoposide—peripheral nervous system neoplasm	0.000235	0.00109	CcSEcCtD
Carfilzomib—Constipation—Etoposide—peripheral nervous system neoplasm	0.000235	0.00109	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.00109	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.00108	CcSEcCtD
Carfilzomib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000232	0.00108	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000232	0.00108	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.00105	CcSEcCtD
Carfilzomib—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000225	0.00105	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.00105	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000224	0.00104	CcSEcCtD
Carfilzomib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000223	0.00104	CcSEcCtD
Carfilzomib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.00103	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.00102	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.00102	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000217	0.00101	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000215	0.001	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000215	0.001	CcSEcCtD
Carfilzomib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000215	0.001	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000994	CcSEcCtD
Carfilzomib—Headache—Vincristine—peripheral nervous system neoplasm	0.000212	0.000989	CcSEcCtD
Carfilzomib—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000209	0.000973	CcSEcCtD
Carfilzomib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000205	0.000955	CcSEcCtD
Carfilzomib—Nausea—Vincristine—peripheral nervous system neoplasm	0.000201	0.000938	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000936	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000929	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.00092	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000197	0.000917	CcSEcCtD
Carfilzomib—Chills—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000905	CcSEcCtD
Carfilzomib—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00019	0.000887	CcSEcCtD
Carfilzomib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000188	0.000875	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000866	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000849	CcSEcCtD
Carfilzomib—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000181	0.000846	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000844	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000838	CcSEcCtD
Carfilzomib—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000178	0.000829	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000174	0.000813	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000812	CcSEcCtD
Carfilzomib—Headache—Etoposide—peripheral nervous system neoplasm	0.000172	0.000801	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000786	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000786	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000781	CcSEcCtD
Carfilzomib—Cough—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000766	CcSEcCtD
Carfilzomib—Nausea—Etoposide—peripheral nervous system neoplasm	0.000163	0.00076	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000163	0.000758	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000751	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000748	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000727	CcSEcCtD
Carfilzomib—Infection—Epirubicin—peripheral nervous system neoplasm	0.000153	0.000712	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000709	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000702	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000702	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000692	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000683	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000659	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000653	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000649	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000648	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000639	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000632	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000623	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000618	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000613	CcSEcCtD
Carfilzomib—Pain—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000613	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000604	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.0006	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000591	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000577	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000572	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000567	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000567	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000567	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000524	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000514	CcSEcCtD
Carfilzomib—ABCB1—cerebellum—peripheral nervous system neoplasm	0.00011	0.0059	CbGeAlD
Carfilzomib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000105	0.00049	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000476	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000474	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—peripheral nervous system neoplasm	9.78e-05	0.000456	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	9.73e-05	0.000454	CcSEcCtD
Carfilzomib—Headache—Epirubicin—peripheral nervous system neoplasm	9.63e-05	0.000449	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.000439	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—peripheral nervous system neoplasm	9.13e-05	0.000426	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.000422	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—peripheral nervous system neoplasm	8.91e-05	0.000415	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000394	CcSEcCtD
Carfilzomib—PSMB8—Metabolism of mRNA—AKT1—peripheral nervous system neoplasm	6.83e-05	0.000486	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	6.8e-05	0.000483	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	6.77e-05	0.000481	CbGpPWpGaD
Carfilzomib—PSMB1—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	6.73e-05	0.000479	CbGpPWpGaD
Carfilzomib—PSMB2—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	6.73e-05	0.000479	CbGpPWpGaD
Carfilzomib—PSMB5—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	6.73e-05	0.000479	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.72e-05	0.000478	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.69e-05	0.000475	CbGpPWpGaD
Carfilzomib—PSMB8—RNF mutants show enhanced WNT signaling and proliferation—AKT1—peripheral nervous system neoplasm	6.64e-05	0.000472	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.62e-05	0.000471	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.62e-05	0.000471	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.62e-05	0.000471	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HGF—peripheral nervous system neoplasm	6.56e-05	0.000466	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HGF—peripheral nervous system neoplasm	6.56e-05	0.000466	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HGF—peripheral nervous system neoplasm	6.56e-05	0.000466	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.53e-05	0.000464	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—TH—peripheral nervous system neoplasm	6.53e-05	0.000464	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—TH—peripheral nervous system neoplasm	6.53e-05	0.000464	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—TH—peripheral nervous system neoplasm	6.53e-05	0.000464	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HGF—peripheral nervous system neoplasm	6.47e-05	0.00046	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—TH—peripheral nervous system neoplasm	6.43e-05	0.000457	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.41e-05	0.000455	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.38e-05	0.000453	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—MYC—peripheral nervous system neoplasm	6.37e-05	0.000453	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	6.36e-05	0.000452	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—MYC—peripheral nervous system neoplasm	6.34e-05	0.00045	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—PTPN11—peripheral nervous system neoplasm	6.32e-05	0.000449	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—PTPN11—peripheral nervous system neoplasm	6.29e-05	0.000447	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	6.26e-05	0.000445	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	6.25e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	6.25e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	6.25e-05	0.000444	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	6.24e-05	0.000443	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	6.24e-05	0.000443	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	6.24e-05	0.000443	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	6.23e-05	0.000443	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling by WNT in cancer—AKT1—peripheral nervous system neoplasm	6.17e-05	0.000438	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	6.15e-05	0.000437	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.96e-05	0.000423	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.96e-05	0.000423	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.96e-05	0.000423	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism of RNA—AKT1—peripheral nervous system neoplasm	5.93e-05	0.000422	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism of RNA—AKT1—peripheral nervous system neoplasm	5.93e-05	0.000422	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism of RNA—AKT1—peripheral nervous system neoplasm	5.93e-05	0.000422	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.88e-05	0.000418	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.87e-05	0.000417	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.85e-05	0.000416	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism of RNA—AKT1—peripheral nervous system neoplasm	5.85e-05	0.000416	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PTPN11—peripheral nervous system neoplasm	5.83e-05	0.000415	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PTPN11—peripheral nervous system neoplasm	5.81e-05	0.000413	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.52e-05	0.000392	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	5.4e-05	0.000384	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	5.4e-05	0.000384	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	5.4e-05	0.000384	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—GNAS—peripheral nervous system neoplasm	5.33e-05	0.000379	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—GNAS—peripheral nervous system neoplasm	5.33e-05	0.000379	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—GNAS—peripheral nervous system neoplasm	5.33e-05	0.000379	CbGpPWpGaD
Carfilzomib—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	5.32e-05	0.000378	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	5.32e-05	0.000378	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—GNAS—peripheral nervous system neoplasm	5.25e-05	0.000373	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—peripheral nervous system neoplasm	5.23e-05	0.000372	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ABCB1—peripheral nervous system neoplasm	5.23e-05	0.000372	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ABCB1—peripheral nervous system neoplasm	5.23e-05	0.000372	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ABCB1—peripheral nervous system neoplasm	5.23e-05	0.000372	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—peripheral nervous system neoplasm	5.2e-05	0.00037	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000366	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000366	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	5.16e-05	0.000366	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ABCB1—peripheral nervous system neoplasm	5.15e-05	0.000366	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.09e-05	0.000362	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.09e-05	0.000362	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.09e-05	0.000362	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	5.08e-05	0.000361	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.02e-05	0.000357	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—ERBB2—peripheral nervous system neoplasm	4.99e-05	0.000355	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—ERBB2—peripheral nervous system neoplasm	4.97e-05	0.000353	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.85e-05	0.000345	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.85e-05	0.000345	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.85e-05	0.000345	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MYC—peripheral nervous system neoplasm	4.83e-05	0.000343	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MYC—peripheral nervous system neoplasm	4.83e-05	0.000343	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MYC—peripheral nervous system neoplasm	4.83e-05	0.000343	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PTPN11—peripheral nervous system neoplasm	4.79e-05	0.00034	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PTPN11—peripheral nervous system neoplasm	4.79e-05	0.00034	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PTPN11—peripheral nervous system neoplasm	4.79e-05	0.00034	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.79e-05	0.00034	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MYC—peripheral nervous system neoplasm	4.76e-05	0.000338	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	4.75e-05	0.000337	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	4.75e-05	0.000337	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	4.75e-05	0.000337	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PTPN11—peripheral nervous system neoplasm	4.72e-05	0.000335	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	4.68e-05	0.000333	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	4.63e-05	0.000329	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—ERBB2—peripheral nervous system neoplasm	4.61e-05	0.000328	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—ERBB2—peripheral nervous system neoplasm	4.59e-05	0.000326	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.58e-05	0.000326	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.56e-05	0.000324	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.45e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.45e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.45e-05	0.000317	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PTPN11—peripheral nervous system neoplasm	4.42e-05	0.000314	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PTPN11—peripheral nervous system neoplasm	4.42e-05	0.000314	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PTPN11—peripheral nervous system neoplasm	4.42e-05	0.000314	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.39e-05	0.000312	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PTPN11—peripheral nervous system neoplasm	4.36e-05	0.00031	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.2e-05	0.000299	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.16e-05	0.000296	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.08e-05	0.00029	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.07e-05	0.000289	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.05e-05	0.000288	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.03e-05	0.000286	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	3.99e-05	0.000283	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—peripheral nervous system neoplasm	3.96e-05	0.000282	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—peripheral nervous system neoplasm	3.96e-05	0.000282	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—peripheral nervous system neoplasm	3.96e-05	0.000282	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—peripheral nervous system neoplasm	3.91e-05	0.000278	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	3.82e-05	0.000272	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NRAS—peripheral nervous system neoplasm	3.8e-05	0.00027	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ERBB2—peripheral nervous system neoplasm	3.78e-05	0.000269	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ERBB2—peripheral nervous system neoplasm	3.78e-05	0.000269	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ERBB2—peripheral nervous system neoplasm	3.78e-05	0.000269	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NRAS—peripheral nervous system neoplasm	3.78e-05	0.000269	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ERBB2—peripheral nervous system neoplasm	3.73e-05	0.000265	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	3.68e-05	0.000262	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—peripheral nervous system neoplasm	3.52e-05	0.00025	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NRAS—peripheral nervous system neoplasm	3.51e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—peripheral nervous system neoplasm	3.5e-05	0.000249	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ERBB2—peripheral nervous system neoplasm	3.49e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ERBB2—peripheral nervous system neoplasm	3.49e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ERBB2—peripheral nervous system neoplasm	3.49e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—NRAS—peripheral nervous system neoplasm	3.49e-05	0.000248	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000247	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000247	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000247	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ERBB2—peripheral nervous system neoplasm	3.44e-05	0.000245	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.42e-05	0.000243	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.35e-05	0.000238	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.28e-05	0.000233	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—peripheral nervous system neoplasm	3.27e-05	0.000232	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—peripheral nervous system neoplasm	3.25e-05	0.000231	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.23e-05	0.000229	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.21e-05	0.000228	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.1e-05	0.00022	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.1e-05	0.00022	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.1e-05	0.00022	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.07e-05	0.000218	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.05e-05	0.000217	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.02e-05	0.000215	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.93e-05	0.000208	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.92e-05	0.000207	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NRAS—peripheral nervous system neoplasm	2.88e-05	0.000205	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NRAS—peripheral nervous system neoplasm	2.88e-05	0.000205	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NRAS—peripheral nervous system neoplasm	2.88e-05	0.000205	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NRAS—peripheral nervous system neoplasm	2.84e-05	0.000202	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—peripheral nervous system neoplasm	2.78e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—peripheral nervous system neoplasm	2.77e-05	0.000197	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.69e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—peripheral nervous system neoplasm	2.67e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—peripheral nervous system neoplasm	2.67e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—peripheral nervous system neoplasm	2.67e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—peripheral nervous system neoplasm	2.66e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—peripheral nervous system neoplasm	2.66e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—peripheral nervous system neoplasm	2.66e-05	0.000189	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—peripheral nervous system neoplasm	2.63e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—peripheral nervous system neoplasm	2.62e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—peripheral nervous system neoplasm	2.57e-05	0.000182	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—peripheral nervous system neoplasm	2.55e-05	0.000181	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—peripheral nervous system neoplasm	2.48e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—peripheral nervous system neoplasm	2.48e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—peripheral nervous system neoplasm	2.48e-05	0.000176	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.46e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—peripheral nervous system neoplasm	2.45e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.45e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.45e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.45e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.44e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—peripheral nervous system neoplasm	2.44e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—peripheral nervous system neoplasm	2.44e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—peripheral nervous system neoplasm	2.44e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—peripheral nervous system neoplasm	2.43e-05	0.000173	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	2.42e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.41e-05	0.000171	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.29e-05	0.000163	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.28e-05	0.000162	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.27e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—peripheral nervous system neoplasm	2.27e-05	0.000161	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—peripheral nervous system neoplasm	2.25e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.22e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.22e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.22e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.19e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—peripheral nervous system neoplasm	2.11e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—peripheral nervous system neoplasm	2.11e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—peripheral nervous system neoplasm	2.11e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—peripheral nervous system neoplasm	2.08e-05	0.000148	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	2.04e-05	0.000145	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.95e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000138	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.92e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—peripheral nervous system neoplasm	1.92e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—peripheral nervous system neoplasm	1.9e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—peripheral nervous system neoplasm	1.89e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.88e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.87e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—peripheral nervous system neoplasm	1.85e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.84e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—peripheral nervous system neoplasm	1.83e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—peripheral nervous system neoplasm	1.82e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.8e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.79e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.73e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.73e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.73e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—peripheral nervous system neoplasm	1.72e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.71e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—peripheral nervous system neoplasm	1.69e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.59e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.58e-05	0.000112	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.57e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.44e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—peripheral nervous system neoplasm	1.44e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—peripheral nervous system neoplasm	1.44e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.42e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.42e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.42e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.4e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.36e-05	9.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.36e-05	9.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.36e-05	9.68e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.34e-05	9.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.2e-05	8.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.2e-05	8.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.2e-05	8.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.19e-05	8.42e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	4.23e-06	3.01e-05	CbGpPWpGaD
